•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Dividend Champion, Contender, And Challenger Highlights: Week August 16
Assenagon Asset Management S.A. Has $5.48 Million Position in Dolby Laboratories $DLB
Here's Why Dolby Laboratories (DLB) is a Strong Growth Stock
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)
Can Dolby's Fiscal Q4 Growth Outlook Overcome Licensing Volatility?
Is Dolby Stock Worth Buying as Growth Meets Near-Term Execution Risks?
Why Dolby Labs Stock Popped Today
Dolby's Q3 Earnings Beat Estimates on Lower Operating Expenses
Dolby Laboratories Q3 Earnings Call Highlights
Dolby Laboratories (DLB) Q3 Earnings Beat Estimates
Dolby Laboratories (DLB) Reports Q3 Earnings: What Key Metrics Have to Say
Dolby Laboratories, Inc. (DLB) Q3 2026 Earnings Call Transcript
Dolby Laboratories Reports Third Quarter 2026 Financial Results
Aristotle Global Equity Advisory Q2 2026 Portfolio Review
Dolby Laboratories Valuation Is Compelling Ahead Of Earnings
Dolby Laboratories Announces Conference Call and Webcast for Q3 Fiscal 2026 Financial Results
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
Cognition Therapeutics: Clearer FDA Path, But Potential Dilution Risks Remain
Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes
3 Audio Video Stocks to Watch as Industry Witnesses Headwinds